April 1st, 2020

The project proposal named ‘PROFILUX – Saliva- and blood-based lung cancer detection based on tumour auto-antibody profiling’ has been selected to receive funding from the EU Eurostars Programme. The company received the official communication in January and the project started on April. The international research consortium where PROALT participates is leaded by InSol Co., Ltd. (South Korea), and the partners Austrian Institute of Technology GmbH and Datamedrix GmbH (Austria), and the Asan Medical Center (Korea).

The project goal is to develop an in vitro diagnostic (IVD) test for early lung cancer (LC) detection using blood and saliva, based on tumour autoantibodies (AAbs) profiling. AAbs can be detected long before clinical symptoms become overt, making them ideal tools for early LC detection.

The Eurostars programme is a funding and support European joint programme co-funded from the national budgets of 36 EUREKA countries and by the European Union through Horizon 2020, aimed at R&D-performing SMEs that wish to exploit the benefits that come with international collaboration.

The Eurostars application PROFILUX passed through a highly competitive selection process scrutinised by a panel of international research and business experts who has selected it based on the innovative business idea and the strongest partnerships.

PROALT will receive support at the national level through the funding agency Centro para el Desarrollo Tecnológico e Industrial (CDTI).